**Table S7a.** Raw data of therapeutic modalities of patients with covid-19 nephropathy.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Treatment** | **Oxygen** | **HD** | **Antihypertensive drugs** | **Moxifloxacin** | **lopin/ritonavir** | **Oseltamivir** | **CVVHDF** | **Arbidol** | **Losartan** | **Belatacept** | **Prednisone** | **MMF** | **Mechanical ventilation** | **Cyclosporine** | **ATG** | **Basiliximab** | **Amoxi-clav** |
| **Tang** | nasal oxygen | + |  | 400 mg/d | 2 tab twice/d |  |  |  |  |  |  |  |  |  |  |  |  |
| **Fu** | 4-5 l/min | + |  |  |  | 75 mg bid | 5 times | 200 mg tid |  |  |  |  |  |  |  |  |  |
| **Ferrey** |  | + |  |  |  |  |  |  | 25 mg daily |  |  |  |  |  |  |  |  |
| **Huang** | 10 L/min |  |  | /d | 200 mg thrice |  |  |  |  |  |  |  | + |  |  |  |  |
| **Huang** | HFHOIT |  |  | + |  | + |  |  |  |  |  |  | + |  |  |  |  |
| **Seminari** | nasal cannula | + | + | 400 mg/d | LPV/r (2 tab) |  |  |  | + |  | + | + |  |  | + | + | 1 gr tid |
| **Chen** | O2 inhalation |  |  | 400 mg/d |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Chen** |  |  |  | 400 mg/d |  | 75 mg bid |  |  |  |  |  |  |  |  |  |  |  |
| **Chen** |  |  |  | 400 mg/d |  | 75 mg bid |  |  |  |  |  |  |  |  |  |  |  |
| **Bussalino** | 4 l/min |  |  |  |  | 30 mg/d |  |  |  |  | 5 mg,15mg | 360 mg bid |  |  | + | + | + |
| **Fontana** | low flow |  |  |  |  |  |  |  |  |  |  |  |  | +, half |  |  |  |
| **Kim** |  |  |  |  | 400/100 mg bid |  |  |  |  |  | 10 mg /d | 500mgbid |  | 1/2 dose |  |  |  |
| **Kim** |  | + |  |  | 400/100 mg bid |  |  |  |  |  | 10 mg /d | 500 mg bid |  |  |  |  |  |
| **Banerjee** |  |  |  |  |  |  |  |  |  |  | 5mg/d |  |  |  |  |  |  |
| **Banerjee** |  | + |  |  |  |  | + |  |  |  | 5 mg/d | 250 mg bid |  |  |  |  |  |
| **Banerjee** |  | + |  |  |  |  | + |  |  |  |  |  |  |  |  |  |  |
| **Banerjee** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Banerjee** |  | + |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Banerjee** |  | + |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Banerjee** |  | +, 1 session |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Guillen** | high flux nasal |  |  |  | 400/100 bid |  |  |  | 50 mg bid |  | + |  |  |  |  |  |  |
| **Karami** |  |  |  |  | + | + |  |  |  |  |  |  | + |  |  |  |  |
| **Kissling** | 4 l/min |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **sharifi-Razavi** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |
| **Zhu** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Marx** |  |  |  |  |  |  |  |  |  | + | + | + | + | 50 mg bid |  |  |  |
| **Hartman** |  |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |
| **Rabdel 1** |  |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |
| **Rabdel 2** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Gaillard** |  | + |  |  | + |  |  |  |  |  |  |  |  |  |  |  |  |
| **Vischini** | IOI via nasal cannula | + |  |  | + |  |  |  |  |  | + | + |  | + |  |  |  |
| **Wang 1** | + | CHD |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Wang 2** |  | CHD |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Wang 3** |  | CHD |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Wang 4** |  | CHD |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Wang 5** |  | CHD |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Wang** | + |  |  |  | + |  |  |  |  |  | + | + |  | + |  |  |  |
| **Larsen** | 2-3 l/min | + |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Suwanwungse** |  |  |  |  |  |  |  |  | + |  |  |  |  |  |  |  |  |
| **Bartiromo** |  |  |  |  | + |  |  |  |  |  |  | + |  | + |  | + |  |
| **Zhu** |  |  |  | + |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Cappel** | + |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |
| **Merziehr** | + |  |  |  | + |  |  |  |  |  | + |  |  |  |  |  |  |
| **Chenna** |  |  |  |  |  |  |  |  |  |  | + | + | + |  |  |  |  |
| **Prattes** |  |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |
| **Deliwala** |  |  |  |  |  |  |  |  |  |  |  |  | + |  |  |  |  |
| **khatri** |  |  |  |  |  |  |  |  | + |  | + | + |  |  |  |  |  |
| **Post-1** | high flow |  |  |  |  |  |  |  | + |  | + | + |  |  |  |  |  |
| **Post-2** | 15 L |  |  |  |  |  | + |  |  |  |  |  | + |  |  |  |  |
| **Taghizadeh** | O2  | + |  |  | + | + |  |  |  |  | + |  | + |  |  |  |  |
| **Cinar** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Pegler** |  | + |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Rinaldi** | + |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Bemtgen** |  |  |  |  | + |  |  |  |  |  |  |  |  |  |  |  |  |
| **Arpali** |  |  |  |  |  | + |  |  |  |  | + | + |  |  |  |  |  |
| **Machado** | + |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |
| **Zeng** | + high flow |  |  |  | + |  |  |  |  |  | + | + | + |  |  |  |  |
| **Resch** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Lazareth** |  |  |  |  |  |  |  |  |  |  | + | + |  |  |  |  |  |

ATG, antithymoglobulin; CHD, chronic hemodialysis; CVVHDF, continuous venovenous hemodiafiltration; HD, hemodialysis. Positive sign indicates presence and negative sign depicts absence of it.